Tag Archives: houston

Laying siege to chemoresistance

But there is still a long way to go. The experimental work has been done on cells. Not on mice, let alone on humans. However, a joint piece of research between the UPV/EHU-University of the Basque Country, the MD Anderson Cancer Center Madrid ―the Spanish subsidiary of the MD Anderson Cancer Center of Houston (Texas)―, and the National Centre for Oncological Research (CNIO) is suggesting that the study of gene expression in chemoresistant lymphomata could help to identify possible therapeutic targets and open up new channels of treatment. …

Early stages breast cancer could soon be diagnosed from blood samples

With a New York University Cancer Institute colleague, the researchers report in an upcoming Clinical Chemistry (now online) that the mixture of free-floating blood proteins created by the enzyme carboxypeptidase N accurately predicted the presence of early-stage breast cancer tissue in mice and in a small population of human patients. "In this paper we link the catalytic activity of carboxypeptidase N to tumor progression in clinical samples from breast cancer patients and a breast cancer animal model," said biomedical engineer Tony Hu, Ph.D., who led the project. "Our results indicate that circulating peptides generated by CPN can serve as clear signatures of early disease onset and progression." The technology is not yet available to the public, and may not be for years. More extensive clinical tests are needed, and those tests are expected to begin in early 2014…

Gene therapy using lentivirus to treat Wiskott-Aldrich Syndrome promising

The new research, led by researchers at the San Raffaele Telethon Institute for Gene Therapy in Milan, Italy was published in Science Express. The disorder that weakens the body’s immune system is caused by a mutation in a gene that encodes the protein WASP. The most often used therapy is a bone marrow or stem cell transplant from a matching donor — often a sibling or relative…

Mouse study predicts cancer drug responsiveness in human tumors

UNC scientists used GEMMs to develop biomarkers for challenging molecular subtypes of human breast cancer, those for which there are fewer targets and therapies. Their work helps to further establish genetically engineered mouse models as predictors of human response to therapy. The molecular subtypes of breast cancer that the UNC group focused on — basal-like, luminal B, and claudin-low — are the most challenging types of breast cancer because these are tumors that don’t typically respond to drugs such as Herceptin or aromatase inhibitors. UNC was among the first to characterize these tumor subtypes, and this new report extends the understanding of them. …

Men who can’t produce sperm face increased cancer risk

"An azoospermic man’s risk for developing cancer is similar to that for a typical man 10 years older," said Michael Eisenberg, MD, PhD, assistant professor of urology at the medical school and director of male reproductive medicine and surgery at Stanford Hospital & Clinics. Eisenberg is lead author of the study, published online June 20 in Fertility and Sterility. …

Avastin fails studies in new brain tumor patients

New research raises fresh questions about which cancer patients benefit from Avastin, a drug that lost its approval for treating breast cancer nearly two years ago. Avastin did not prolong life when used as a first treatment for people with brain tumors like the one U.S. Sen. Edward Kennedy died of several years ago, two studies found. In one, patients who were expected to benefit the most from Avastin based on genetic testing had the worst survival rates. Side effects also were more common with Avastin. The drug is approved for treating brain tumors that have recurred for people who already tried chemotherapy or radiation. But that approval was based on studies suggesting it briefly delayed the worsening of the disease. No definitive study shows it helps those patients live longer, either. Something similar happened with breast cancer: Avastin won the Food and Drug Administration's approval after studies suggested it delayed disease progression. But when later research showed it did not prolong life and brought more side effects, its approval for breast cancer was revoked. However, many cancer experts say the same thing should not happen now, and that Avastin should retain its approval for brain cancer patients whose disease has recurred. “I would definitely not want the FDA to take that away from patients,” said Dr. Deepa Subramaniam, director of the brain tumor center at Georgetown Lombardi Comprehensive Cancer Center in Washington, D.C. “That's very different from the breast cancer story,” where there are many other drugs that can be tried, she said. She had no role in the new studies, which were discussed Sunday at an American Society of Clinical Oncology conference in Chicago. Avastin, made by Swiss-based Roche's Genentech unit, acts by depriving tumors of a blood supply. It's also sold for treating certain colon, lung and kidney tumors. Another study discussed Sunday and released previously showed it helped women with advanced cervical cancer live nearly four months longer. The new brain cancer studies tested it as initial treatment for glioblastoma, the most common and deadly type of tumor. About 10,000 Americans each year are diagnosed with these tumors, which are nearly always incurable. In one study, 637 patients received standard chemotherapy plus radiation, and half also received Avastin. Both groups lived about 16 months, and those on Avastin had more side effects - mostly low blood counts, blood clots and high blood pressure. “Our study would strongly suggest that it is not beneficial to do it as front-line treatment but to reserve it as second-line or salvage therapy,” said study leader Dr. Mark Gilbert of the University of Texas MD Anderson Cancer Center in Houston. Federal grants and Genentech paid for the study, and Gilbert consults for the company. More troubling, independent experts said, is that patients who were expected to do the best based on genetic and other tests surprisingly had a worse survival trend - 16 months versus 25 months for others in the study. New research needs to be done to better define which patients benefit, said Rakesh Jain, a brain tumor expert at Massachusetts General Hospital in Boston. “We just cannot give these agents to every patient,” he said. A second study that tested Avastin as initial therapy with radiation and the drug Temodar found it did not prolong life, but patients on Avastin went nearly five months longer before their tumors appeared to worsen. Avastin costs about $43,000 plus doctor infusion charges for a course of treatment for people whose brain tumors have recurred.source : http://www.foxnews.com/health/2013/06/03/avastin-fails-studies-in-new-brain-tumor-patients/